# Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

> **NCT00975000** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 114 (actual)

## Conditions studied

- Chronic Allograft Nephropathy
- Chronic Kidney Disease
- Chronic Renal Failure
- Disordered Mineral Metabolism
- End Stage Renal Disease
- Hyperparathyroidism
- Hypophosphatemia
- Kidney Disease
- Kidney Transplantation
- Post Renal Transplantation

## Interventions

- **DRUG:** Cinacalcet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00975000
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-03
- **Primary completion:** 2012-09-13
- **Final completion:** 2013-04-16
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975000, "Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00975000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*